Life Science Tools & Diagnostics: Expert's Latest Views on Prec. Onc. Heading into ASCO

Research evidence excerpt

Life Science Tools & Diagnostics: Expert's Latest Views on Prec. Onc. Heading into ASCO

Idea

May 22, 2026 11:20 AM GMT

Morgan Stanley & Co. LLCMLife Science Tools & Diagnostics | North America Kallum L Titchmarsh

Equity Analyst

Expert's Latest Views on Prec. Kallum.Titchmarsh@morganstanley.comJakob Dodd +1 212 761-2351

Research Associate

Jakob.Dodd@morganstanley.com +1 212 761-0797

Onc. Heading into ASCO Jason Lai

Jason.Lai@morganstanley.com +1 212 761-4848

Our conversation this week with a high volume GI Oncologist

Life Science Tools & Diagnostics

provided us with a refreshed perspective on the evolving North America

utilization of MRD, CGP, and Screening tests. We also provide Industry View In-Line

our most recent views on key data read-outs heading into ASCO

(May 29 - June 2, Chicago).

Key Takeaways

NTRA Signatera preferred in MRD, though expert's impression of GH Reveal is

improving.

Foundation Medicine (Roche) and TEM are go-to CGP tests in the physician's

practice.

GH Shield-driven CRC volumes modest at present; expert sees more potential for

multi-cancer.

We caught up with a high volume GI Oncologist based in the Northeast for a

conversation centered around Precision Oncology Diagnostics. Please see below for

our key takes from the conversation:

Evidence around MRD less than perfect but highly utilized nonetheless: Our

expert described MRD as core to their practice, with tests run for all

cholangiocarcinoma and Stage III / Stage II post-resection CRC patients, and smaller

but growing pancreatic and gastric volumes. Unsurprisingly, better sensitivity and

predictive value were cited as key reasons for preferring NTRA Signatera's tissue-

informed approach, though the physician called out the benefit of (tumor-naïve) GH